Takeda recently announced that the U.S. Food and Drug Administration (FDA) has approved VONVENDI® for routine prophylaxis to reduce the frequency of bleeding episodes in adults with severe Type 3 von Willebrand disease (VWD) receiving on-demand therapy.
CSL Behring announced that the company’s distribution agreement with Ferring Pharmaceuticals for STIMATE® nasal spray recently expired and will not be renewed effectively removing this medication as a valuable treatment opti
NHF's Wednesday Webinars for May 2021 will focus on Women's Health Month, featuring topics of interest to both patients and healthcare providers who are interested in issues faced by women with inheritable blood disorders.
The von Willebrand disease (VWD) pre-conference brings together the VWD community to connect in a lively, engaging and supportive educational environment. This year, we will focus on the elements of reconnecting, rebuilding and refocusing as a community. We will explore the many ways that we as a community can help raise awareness of VWD and help those who are unaware of their status. We’ll also discuss new medical updates and NHF’s course of action with VWD. Sponsored by CSL Behring.
2020 is the year that VWD guidelines will be announced. This will be an opportunity to learn, explore, and understand the new measures for treatment, diagnosis, and protocols.
This session will review the signs and symptoms of von Willebrand disease, discuss genetics and inheritance patterns, and define and compare the three types of VWD. The presentation will also cover laboratory diagnosis and its challenges, and the therapeutic options available for people with VWD. In addition, you will learn important skills to advocate for yourself and loved ones.
A research abstract presented at the recent Thrombosis & Haemostasis Summit of North America 2020 Virtual Conference suggested that epidural analgesia may be a safe option for pregnant women with von Willebrand disease (VWD) type 1, provided clotting factors are maintained at certain levels.